Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05184322Phase 1Completed

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Role: lead

NCT05111912Phase 2Completed

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Role: lead

NCT05083117Phase 2Withdrawn

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

Role: lead

NCT04389775Phase 1Completed

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants

Role: lead

All 4 trials loaded